CORRECTION article

Front. Cardiovasc. Med., 19 June 2023

Sec. Cardiovascular Epidemiology and Prevention

Volume 10 - 2023 | https://doi.org/10.3389/fcvm.2023.1186990

Corrigendum: Cardiovascular risk according to body mass index in reproductive-aged women with polycystic ovary syndrome: a systematic review and meta-analysis

  • 1. Hypertension Center, Lanzhou University Second Hospital, Lanzhou, China

  • 2. School of Public Health, Lanzhou University, Lanzhou, China

Error in Figure/Table

In the published article, there was an error in [Table 1Search strategies] as published. [We had searched PubMed for the first set of results in Table 1 and not PubMed-MEDLINE]. The corrected caption in [Table 1Search strategies] is **[PubMed] which appears below.

PubMed

In the published article, there was an error in [Table 2 Characteristics of included studies in the meta-analysis]. The corrected [Table 2 Characteristics of included studies in the meta-analysis] and its caption **[Table 2 Characteristics of included studies in the meta-analysis] appear below.

Table 2

Author/YearPlace of studyType of studyPCOS vs. control (n)Participants ageBMIWHRAndrogen levelOutcomes
Akram (2010)PakistanRetrospective50 vs. 3020–39 yearsPCOS: 23.6 ± 0.50 kg/m2;
Control: 23.5 ± 0.71 kg/m2
HDL-C, LDL-C, TG, nonHDL-C
Adali (2010)TurkeyProspective26 vs. 25PCOS: 24.73 ± 2.91 years;
Control: 25.04 ± 2.26 years
PCOS: 24.40 ± 4.23 kg/m2;
Control: 23.90 ± 3.95 kg/m2
PCOS: 0.74 ± 0.05; Control: 0.73 ± 0.04HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Alexandraki (2006)GreeceCross-section27 vs. 27PCOS: 25.41 ± 0.80 years; Control: 27.33 ± 0.83 yearsPCOS: 27.42 ± 1.12 kg/m2;
Control: 25.05 ± 1.19 kg/m2
PCOS: 0.78 ± 0.01; Control: 0.75 ± 0.01PCOS: 10.85 ± 0.76 nmol/L;
Control: 5.37 ± 0.38 nmol/L
HDL-C, LDL-C, TG, nonHDL-C, SBP, DBP
Arikan (2007)TurkeyProspective39 vs. 30PCOS: 22.82 ± 5.53 years;
Control: 24.64 ± 4.22 years
PCOS: 21.48 ± 6.50 kg/m2;
Control: 20.90 ± 6.04 kg/m2
PCOS: 2.98 ± 1.31 ng/ml;
Control: 1.37 ± 0.89 ng/ml
HDL-C, LDL-C, TG, nonHDL-C
Berneis (2009)ItalyCross-section30 vs. 24PCOS: 25.1 ± 4.2 years;
Control: 25.5 ± 3 years
PCOS: 28.4 ± 5.8 kg/m2;
Control: 28 ± 4.4 kg/m2
HDL-C, LDL-C, TG, nonHDL-C
Cascella (2006)ItalyProspective50 vs. 50PCOS: 21.9 ± 2.7 years;
Control: 22.2 ± 2.8 years
PCOS: 24.6 ± 2.5 kg/m2;
Control: 24.4 ± 2.8 kg/m2
PCOS: 0.86 ± 0.1; Control: 0.83 ± 0.1PCOS: 5.1 ± 0.7 nmol/L;
Control: 1.4 ± 0.6 nmol/L
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Calzada (2018)SpainRetrospective125 vs. 169PCOS: 28.0 ± 5.0 years;
Control: 30.0 ± 6.0 years
PCOS: 25.7 ± 7.1 kg/m2;
Control: 22.3 ± 3.1 kg/m2
PCOS: 2.73 ± 1.35 ng/ml;
Control: 2.17 ± 1.05 ng/ml
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Cetinkalp (2009)TurkeyProspective129 vs. 91PCOS: 24.58 ± 4.61 years;
Control: 25.48 ± 3.38 years
PCOS: 24.47 ± 4.64 kg/m2;
Control: 24.20 ± 3.31 kg/m2
HDL-C, LDL-C, TG, nonHDL-C
Cheng (2015)ChinaProspective103 vs. 96PCOS: 26 ± 4 years;
Control: 26 ± 2 years
PCOS: 24.2 ± 5.3 kg/m2
Control: 20.5 ± 2.7 kg/m2
PCOS: 0.9 ± 0.3; Control: 0.8 ± 0.1HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Cussons (2009)AustraliaCross-section19 vs. 19PCOS: 30.4 ± 5.54 years;
Control: 34.44 ± 7.8 years
PCOS: 24.1 ± 2.9 kg/m2
Control: 22.9 ± 3.2 kg/m2
PCOS: 0.8 ± 0.1; Control: 0.8 ± 0.6PCOS: 10.89 ± 3.99 nmol/L;
Control: 8.54 ± 2.41 nmol/L
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Diamanti-Kandarakis (2006)GreeceProspective25 vs. 25PCOS: 25.64 ± 0.86 years;
Control: 27.52 ± 1.02 years
PCOS: 29.08 ± 1.43 kg/m2;
Control: 26.22 ± 1.16 kg/m2
PCOS: 0.79 ± 0.01; Control: 0.75 ± 0.01HDL-C, SBP, DBP, nonHDLC
El-Kannishy (2010)EgyptCross-section14 vs. 10PCOS: 25.2 ± 3.6 years;
Control: 24.4 ± 4.07 years
PCOS: 22.8 ± 2.1 kg/m2
Control: 21.9 ± 2.97 kg/m2
HDL-C, LDL-C, TG, nonHDL-C
Erdogan (2007)USARetrospective68 vs. 26PCOS: 24.27 ± 5.44 years;
Control: 26.41 ± 5.65 years
PCOS: 24.41 ± 5.43 kg/m2
Control: 23.35 ± 5.04 kg/m2
HDL-C, LDL-C, TG, nonHDL-C
Erdogan (2009)USARetrospective88 vs. 119PCOS: 24.07 ± 1.32 years; Control: 25.01 ± 2.05 yearsPCOS: 24.38 ± 4.13 kg/m2
Control: 23.47 ± 4.12 kg/m2
HDL-C, LDL-C, TG, nonHDL-C
Glintborg (2013)DenmarkProspective30 vs. 14PCOS: 32.3 ± 7.9 years;
Control: 34.3 ± 12.4 years
PCOS: 33.5 ± 4.2 kg/m2;
Control: 32.8 ± 7.1 kg/m2
TG
Gonzalez (2020)USACross-sectionLean: 10 vs. 10; Obese: 9 vs. 9Lean: PCOS: 27 ± 1 years;
Control: 29 ± 2 years;
Obese: PCOS: 28 ± 2 years;
Control: 32 ± 2 years
Lean: PCOS: 22.5 ± 0.6 kg/m2;
Control: 22.0 ± 0.8 kg/m2;
Obese: PCOS: 34.4 ± 0.9 kg/m2;
Control: 34.1 ± 0.7 kg/m2
Lean: PCOS: 4.1 ± 0.4 ng/ml;
Control: 1.8 ± 0.8 ng/ml;
Obese: PCOS: 3.8 ± 0.3 ng/ml;
Control: 2.0 ± 0.2 ng/ml
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Kargili (2010)TurkeryCross-section168 vs. 52PCOS: 25.7 ± 5.5 years;
Control: 26.1 ± 5.4 years
PCOS: 26.8 ± 3.4 kg/m2;
Control: 25.4 ± 2.8 kg/m2
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Ketel (2010)NetherlandsCross-sectionLean: 22 vs. 17
Obese: 18 vs. 13
Lean: PCOS: 28.6 ± 4.5 years; Control: 27.7 ± 5.3 years;
Obese: PCOS: 30.3 ± 4.2 years; Control: 28.6 ± 5.3 years
Lean: PCOS: 22.0 ± 2.2 kg/m2;
Control: 22.2 ± 1.7 kg/m2;
Obese: PCOS: 36.2 ± 5.9 kg/m2;
Control: 40.5 ± 7.0 kg/m2
Lean: PCOS: 0.78 ± 0.05;
Control: 0.76 ± 0.03;
Obese: PCOS: 0.84 ± 0.05;
Control: 0.80 ± 0.01
Lean: PCOS: 7.0 ± 1.8 nmol/L;
Control: 4.8 ± 1.2 nmol/L;
Obese: PCOS: 7.7 ± 2.4 nmol/L;
Control: 4.9 ± 1.7 nmol/L
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Legro (2001)USACross-sectionLean: 42 vs. 27; Obese: 153 vs. 35Lean: PCOS: 25 ± 6 years;
Control: 29 ± 7 years;
Obese: PCOS: 28 ± 5 years;
Control: 32 ± 7 years
Lean: PCOS: 23.1 ± 2.4 kg/m2;
Control: 23.0 ± 1.8 kg/m2;
Obese: PCOS: 37.0 ± 6.9 kg/m2;
Control: 37.7 ± 6.4 kg/m2
Lean: PCOS: 0.76 ± 0.07;
Control: 0.75 ± 0.06;
Obese: PCOS: 0.85 ± 0.10;
Control: 0.79 ± 0.06
Lean: PCOS: 2,553 ± 1,367 ng/ml;
Control: 1,628 ± 734 ng/ml;
Obese: PCOS: 2,476 ± 1,140 ng/ml;
Control: 1,533 ± 720 ng/mla
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Liang (2012)TaiwanProspectiveLean: 110 vs. 50; Obese: 110 vs. 20Lean: PCOS: 26.8 ± 5.1 years;
Control: 28.1 ± 4.2 years
Obese: PCOS: 27.0 ± 6.4 years;
Control: 29.0 ± 5.1 years
Lean: PCOS: 20.6 ± 2.0 kg/m2;
Control: 20.4 ± 2.0 kg/m2;
Obese: PCOS: 31.1 ± 3.9 kg/m2;
Control: 30.4 ± 3.7 kg/m2
Lean: PCOS: 0.79 ± 0.06;
Control: 0.82 ± 0.14;
Obese: PCOS: 0.89 ± 0.08;
Control: 0.85 ± 0.08
HDL-C, LDL-C, TG, nonHDL-C
Long (2019)ChinaCross-section387 vs. 150PCOS: 27.0 ± 4.5 years;
Control: 25.3 ± 2.2 years
PCOS: 25.4 ± 4.6 kg/m2;
Control: 20.7 ± 2.6 kg/m2
PCOS: 0.86 ± 0.06; Control: 0.80 ± 0.07HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Luque-Ramirez (2007)SpainCross-sectionLean: 11 vs. 8; Overweight: 13 vs. 4; Obese: 16 vs. 8Lean: PCOS: 23.0 ± 5.4 years;
Control: 24.8 ± 6.0 years;
Overweight: PCOS: 23.6 ± 4.6 years; Control: 29.3 ± 10.3 years;
Obese: PCOS: 26.3 ± 6.7 years;
Control: 28.5 ± 5.8 years
Lean: PCOS: 22.2 ± 2.0 kg/m2;
Control: 21.3 ± 1.3 kg/m2;
Overweight: PCOS: 27.5 ± 1.8 kg/m2;
Control: 27.4 ± 1.5 kg/m2
Obese: PCOS: 35.8 ± 3.9 kg/m2;
Control: 35.5 ± 3.2 kg/m2
Lean: PCOS: 0.73 ± 0.06;
Control: 0.73 ± 0.06;
Overweight: PCOS: 0.79 ± 0.07; Control: 0.79 ± 0.04;
Obese: PCOS: 0.88 ± 0.09;
Control: 0.83 ± 0.08
PCOS: 12.7 ± 3.6 nmol/L;
Control: 7.2 ± 2.2 nmol/L
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Macut (2008)SerbiaProspective75 vs. 51PCOS: 23.1 ± 5.1 years;
Control: 24.6 ± 4.1 years
PCOS: 24.9 ± 4.7 kg/m2;
Control: 23.7 ± 4.0 kg/m2
PCOS: 0.79 ± 0.06; Control: 0.77 ± 0.05HDL-C, LDL-C, TG, nonHDL-C
Meyer (2005)AustraliaRetrospective100 vs. 20PCOS: 32.7 ± 1.8 years;
Control: 33.2 ± 2.3 years
PCOS: 37.3 ± 2.43 kg/m2;
Control: 36.7 ± 1.28 kg/m2
PCOS: 0.86 ± 0.01; Control: 0.84 ± 0.02PCOS: 4.9 ± 0.3 mmol/L;
Control: 3.6 ± 0.4 mmol/La
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Moran (2009)AustraliaCross-section80 vs. 27PCOS: 34.1 ± 6.9 years;
Control: 33.8 ± 6.8 years
PCOS: 36.0 ± 6.6 kg/m2;
Control: 37.4 ± 5.6 kg/m2
PCOS: 0.86 ± 0.08; Control: 0.84 ± 0.06PCOS: 4.8 ± 0.3 µmol/L;
Control: 3.4 ± 0.4 µmol/La
HDL-C, LDL-C, TG, nonHDL-C
Ni (2009)ChinaRetrospective578 vs. 281PCOS: 27.3 ± 3.7 years;
Control: 28.3 ± 3.7 years
PCOS: 22.1 ± 3.7 kg/m2;
Control: 22.2 ± 2.2 kg/m2
PCOS: 5.4 ± 2.5 µmol/L;
Control: 4.4 ± 1.9 µmol/La
TG, SBP, DBP
Oral (2009)TurkeyProspective48 vs. 43PCOS: 23.9 ± 3.3 years;
Control: 24.2 ± 3.9 years
PCOS: 24.1 ± 2.9 kg/m2;
Control: 24.0 ± 1.9 kg/m2
PCOS: 256.3 ± 59.5 µg/dl;
Control: 246.5 ± 59.5 µg/dla
HDL-C, LDL-C, TG, nonHDL-C
Orio (2004)ItalyProspective30 vs. 30PCOS: 22.2 ± 2.5 years;
Control: 22.6 ± 2.3 years
PCOS: 22.4 ± 2.1 kg/m2;
Control: 22.1 ± 1.8 kg/m2
PCOS: 0.77 ± 0.4; Control: 0.72 ± 0.3PCOS: 4,535 ± 527 µmol/L;
Control: 2,988 ± 311 µmol/La
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C,
Philbois (2019)BrazilRetrospective60 vs. 30PCOS without obese: 28.5 ± 5.2 years; PCOS without obese: 30.2 ± 5.3 years; Control: 31.2 ± 6.6 yearsPCOS without obese: 22.9 ± 1.6 kg/m2; PCOS with obese: 33.9 ± 2.4 kg/m2; Control: 23.5 ± 3 kg/m2SBP, DBP
Rizzo (2011)ItalyProspective350 vs. 90PCOS: 24 ± 5 years;
Control: 24 ± 3 years
PCOS: 27 ± 7 kg/m2; Control: 27 ± 4 kg/m2HDL-C, LDL-C, TG, nonHDL-C
Sasaki (2011)JapanProspective54 vs. 24PCOS: 30.2 ± 3.9 years; Control: 31.5 ± 4.4 yearsPCOS: 24.3 ± 5.7 kg/m2;
Control: 22.2 ± 3.4 kg/m2
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Shafiee (2020)UKCross-section34 vs. 34PCOS: 31.8 ± 5.97 years; Control: 43.68 ± 13.12 yearsPCOS: 29.28 ± 2.91 kg/m2;
Control: 28.58 ± 2.62 kg/m2
PCOS: 0.88 ± 0.03; Control: 0.85 ± 0.02HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Shroff (2007)USAProspective24 vs. 24PCOS: 32 ± 6.5 years;
Control: 36 ± 7.2 years
PCOS: 36 ± 5.4 kg/m2;
Control: 35 ± 3.3 kg/m2
PCOS: 0.85 ± 0.1; Control: 0.82 ± 0.1HDL-C, LDL-C, TG
Soares (2009)BrazilCross-section40 vs. 50PCOS: 24.5 ± 3.8 years;
Control: 24.5 ± 5.1 years
PCOS: 22.7 ± 3.3 kg/m2;
Control: 23.1 ± 3.2 kg/m2
HDL-C, LDL-C, TG, SBP, DBP, nonHDL-C
Tarkun (2004)TurkeyProspective37 vs. 25PCOS: 23.45 ± 4.3 years; Control: 24.4 ± 4.07 yearsPCOS: 23.85 ± 3.26 kg/m2;
Control: 22.9 ± 2.97 kg/m2
PCOS: 4.08 ± 2.3 ng/ml;
Control: 2.89 ± 1.1 ng/ml
HDL-C, LDL-C, TG, nonHDL-C
Tiras (1999)TurkeyProspective35 vs. 35PCOS: 24.5 ± 6.0 years;
Control: 23.6 ± 3.9 years
PCOS: 22.9 ± 4.2 kg/m2;
Control: 22.0 ± 1.8 kg/m2
PCOS: 4.05 ± 3.14 ng/ml;
Control: 2.48 ± 0.98 ng/ml
HDL-C, LDL-C, TG, nonHDL-C
Vryonidou (2005)GreeceProspective75 vs. 55PCOS: 23.9 ± 5.4 years;
Control: 24.7 ± 5.3 years
PCOS: 27.3 ± 7.0 kg/m2;
Control: 26.3 ± 7.7 kg/m2
PCOS: 0.79 ± 0.07; Control: 0.75 ± 0.04PCOS: 8.12 ± 9.11 µmol/L;
Control: 6.54 ± 8.59 µmol/La
HDL-C, LDL-C, TG, SBP, nonHDL-C
Yildiz (2002)TurkeyProspective59 vs. 23PCOS: 22.9 ± 4.4 years;
Control: 24.8 ± 4.2 years
PCOS: 23.0 ± 2.4 kg/m2;
Control: 22.1 ± 2.2 kg/m2
PCOS: 0.76 ± 0.02; Control: 0.71 ± 0.02PCOS: 9.4 ± 3.1 nmol/L;
Control: 5.9 ± 1.7 nmol/L
HDL-C, TG, nonHDL-C

Characteristics of included studies in the meta-analysis.

a

Represented that these studies measured the level of dehydroepiandrosterone sulfate, others measured androstenedione level. WHR: Waist-to-hip ratio; BMI: Body mass index; LDL-C: low-density lipoprotein cholesterol; TG: triglyceride; HDL-C: low high-density lipoprotein cholesterol; SBP: Systolic blood pressure; DBP: Diastolic blood pressure.

Figure

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

In the published article, there was an error in (Figure 4) as published. [We have revised Figure 4, in which we had included an incorrect study]. The corrected [Figure 4] and its caption **[Forest plot for comparison of non-high-density lipoprotein-cholesterol in polycystic ovary syndrome vs. control subjects. Studies are classified by different body mass index (BMI) categories (BMI < 25 kg/m2, BMI ≥ 30 kg/m2, and BMI 25–30 kg/m2).] appear above.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Text Correction

In the published article, there was two errors in the method.

1. According to the corrected figure, we revised the result of non-HDL-C].

An error was found in [Methods], [Study selection and criteria], [Page 2]. This sentence previously stated:

“[(4) articles published in languages other than English]” This sentence should be deleted.

2. [The selection criteria for the retrieved articles was unclear in the sixth information].

A correction has been made to [Methods], [Study selection and criteria], [Page 2]. This sentence previously stated:

“[6) each article had to conduct BMI matching]”

The corrected sentence appears below: 6) each article had to conduct BMI matching or the equal BMI (mean)

A correction has been made to [Results], [Lipid profiles], [Page 8]. This sentence previously stated:

“[As shown in Figure 4, non-HDL-C [SMD (95% CI): 0.42 (0.31, 0.52), P < 0.001] increased in reproductive-aged women with PCOS, with significant between-study heterogeneity. The subgroup analysis showed that non-HDL-C increased in women with PCOS at the three BMI levels, including BMI < 25 kg/m2 [SMD (95% CI): 0.40 (0.27, 0.54), P < 0.001], BMI ≥ 30 kg/m2 [MD (95% CI): 0.52 (0.33, 0.70), P < 0.001], and BMI 25–30 kg/m2 [MD (95% CI): 0.37 (0.11, 0.62), P = 0.005]. In this analysis, no publication bias was evident (asymmetry test P = 0.291).]”

The corrected sentence appears below:

“[As shown in Figure 4, non-HDL-C [SMD (95% CI): 0.42 (0.31, 0.53), P < 0.001] increased in reproductive-aged women with PCOS, with significant between-study heterogeneity. The subgroup analysis showed that non-HDL-C increased in women with PCOS at the three BMI levels, including BMI < 25 kg/m2 [SMD (95% CI): 0.40 (0.27, 0.54), P < 0.001], BMI ≥ 30 kg/m2 [MD (95% CI): 0.57 (0.37, 0.77), P < 0.001], and BMI 25–30 kg/m2 [MD (95% CI): 0.37 (0.11, 0.62), P = 0.005].]”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Summary

Keywords

polycystic ovary syndrome, cardiovascular risk, reproductive-age, meta-analysis, body mass index

Citation

Zhuang C, Luo X, Wang W, Sun R, Qi M and Yu J (2023) Corrigendum: Cardiovascular risk according to body mass index in reproductive-aged women with polycystic ovary syndrome: a systematic review and meta-analysis. Front. Cardiovasc. Med. 10:1186990. doi: 10.3389/fcvm.2023.1186990

Received

15 March 2023

Accepted

22 May 2023

Published

19 June 2023

Volume

10 - 2023

Edited and reviewed by

Dexter Canoy, Newcastle University, United Kingdom

Updates

Copyright

*Correspondence: Jing Yu

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics